A Phase 4 interventional study of Placebo in COPD, sponsored by Gelb, Arthur F., M.D.. Completed at 2 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by Gelb, Arthur F., M.D. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 750th largest by enrollment of the 1,039 interventional ones that give a count, is one of 43 that started in 2006, is one of 98 in phase 4, and was the 151st registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,280 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 231 · Phase 3 239 · Phase 4 98
First in 1994; this study’s year is marked. 43 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,039 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 503 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
605 of 1,280 have an industry lead sponsor. The 10 most frequent:
Gelb, Arthur F., M.D. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Gelb, Arthur F., M.D. has 3 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.
Study completed with 29 patients studied. Data is being analyzed to evaluate trough and peak effect of 18 µg tiotropium vs placebo on FEV 1 (L)(forced expiratory capacity in one second), inspiratory capacity and functional residual volume. In addition, we will study the effect of 18 µg tiotropium vs placebo on metronome paced hyperventilation induced dynamic hyperinflation. We will also evaluate the effect of tiotropium induced increase in IC (inspiratory capacity) vs extent of emphysema as evaluated on high resolution thin section CT lung
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
Drug: Placebo
placebo 18ug tiotropium for 1 month
Drug: Placebo
Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)-
Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second
Time frame: 30 days
Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity)
Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients.
Time frame: 30 days
Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo
Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters
Time frame: 30 days
Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo
Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters
Time frame: 30 days
Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo
Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage
Time frame: 30 days
Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo
Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters
Time frame: 30 days
Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo
Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters)
Time frame: 30 days
Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo
Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters)
Time frame: 30 days
Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo
Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
Time frame: 30 days
Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo
Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters
Time frame: 30 days
Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo
Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage
Time frame: 30 days
Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo
Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
Time frame: 30 days
IC (Inspiratory Capacity L)and Metronome Paced Hyperventilation-induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo and Baseline
IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo
Time frame: baseline and 30 days (+2h) post dose
TLC (L) Before and After Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in Tiotropium Cohort Versus Placebo
Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention \& 2 hrs. after after 30 days of treatment with either placebo or tiotropium
Time frame: one hour before intervention & 2 hrs. after after 30 days
Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium
Time frame: baseline to 30 days
IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema
Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema
Time frame: baseline to 30 days
Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema
Time frame: baseline to trough tiotropium
Patients with COPD (chronic obstructive pulmonary disease), GOLD (Global Initiative for Chronic Obstructive Lung Disease)Stage 2 were recruited from pulmonary out-patient offices at Mt. Sinai Hosp. Toronto and from Arthur F Gelb MD Lakewood, Calif from June 2009 thru January 2010
| Milestone | Tiotropium 18 µg Capsule First, Then Placebo | Placebo First, Then Tiotropium Bromide 18 µg |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Milestone | Tiotropium 18 µg Capsule First, Then Placebo | Placebo First, Then Tiotropium Bromide 18 µg |
|---|---|---|
| Started | 15 | 14 |
| 29 days | 15 | 14 |
| Completed | 15 | 14 |
| Not completed | 0 | 0 |
Lung function studies (mean +/- SD): peak FEV1 (+2h) after 30 days of placebo or tiotropium in 29 moderate COPD patients. FEV1 = Forced expiratory volume in one second
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)- | 1.74 ± 0.58 | 1.82 ± 0.59 |
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to FEV 1; correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema; measures include increase in FEV1 from baseline to peak tiotropium
| percentage of lung tissue | Lung CT Scored Emphysema and FEV1 |
|---|---|
| Extent of Lung CT Scored Emphysema and and Lung Function of FEV1(l) After Tiotropium | 13.68 ± 18.84 |
Lung function studies (mean +/- SD): peak FRC after 30 days (+2h) of placebo or tiotropium in 29 moderate COPD patients.
| Liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response:Peak FRC (L) (Functional Residual Capacity) | 3.80 ± 0.79 | 3.72 ± 0.84 |
Lung function studies (mean +/- SD) of peak forced vital capaciy (L) after 30 days (+2h) of tiotropium versus placebo in 29 moderate COPD patients. Forced vital capacity - liters
| liters | Placebo | Tiotropium 18 µg Capsule, Bronchodilator |
|---|---|---|
| Bronchodilator Response: Peak FVC (L) (Forced Vital Capacity)- Tiotropium and Placebo | 3.17 ± 1.13 | 3.27 ± 1.16 |
Correlation between change in inspiratory capacity (L) post metronome paced hyperventilation induced dynamic hyperinflation and extent of lung ct scored emphysema
| percentage of lung tissue | Lung CT Scored Emphysema and IC |
|---|---|
| IC (Inspiratory Capacity, L) Post Mph (Metronome Paced Hyperventilation) Induced dh (Dynamic Hyperinflation) After Tiotropium and Extent of Lung CT Scored Emphysema | 13.68 ± 18.84 |
Lung function studies (mean +/- SD) - Peak inspiratory capacity after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Inspiratory capacity- liters
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Peak IC (L) - (Inspiratory Capacity) - Tiotropium Versus Placebo | 2.12 ± 0.82 | 2.24 ± 0.80 |
Lung function studies (mean +/- SD) peak Peak FRC/TLC after 30 days (+2h)of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity/total lung capacity - percentage
| percentage of FRC/TLC | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Peak FRC/TLC Percentage (Functional Residual Capacity(L)/Total Lung Capacity(L) - Tiotropium or Placebo | 0.65 ± 0.10 | 0.66 ± 0.17 |
Net change in lung function studies (mean +/- SE) from baseline to trough (-1h) and peak (+2h) after 30 days of tiotropium versus placebo in 29 moderate COPD patients. Total lung capacity - liters
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Peak TLC (L) (Total Lung Capacity)- Tiotropium or Placebo | 5.91 ± 1.22 | 5.82 ± 1.35 |
Lung function studies Trough FEV1(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Forced expiratory volume in 1s (liters)
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough FEV1 (L)- (Forced Expiratory Volume) Tiotropium Versus Placebo | 1.68 ± 0.54 | 1.71 ± 0.56 |
Lung function studies Trough FRC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients. Functional residual capacity(liters)
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough FRC (L)- Tiotropium Versus Placebo | 3.84 ± 0.84 | 3.66 ± 0.88 |
Lung function studies Trough FVC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough FVC (L)- (Forced Vital Capacity) Tiotropium Versus Placebo | 3.12 ± 1.10 | 3.15 ± 1.13 |
Lung function studies (Trough IC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough inspiratory capacity- liters
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough IC (L) Inspiratory Capacity - Tiotropium Versus Placebo | 2.17 ± 0.77 | 2.11 ± 0.83 |
Lung function studies Trough FRC/TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients Trough Functional residual capacity/total lung capacity - percentage
| percentage of FRC/TLC | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough FRC/TLC (Functional Residual Capacity/Total Lung Capacity)- Tiotropium Versus Placebo | 0.64 ± 0.09 | 0.62 ± 0.09 |
Lung function studies Trough TLC(mean +/- SD) after 30 days(-1h) of tiotropium versus placebo in 29 moderate COPD patients
| liters | Placebo | Tiotropium |
|---|---|---|
| Bronchodilator Response: Trough TLC (L) (Total Lung Capacity)- Tiotropium Versus Placebo | 5.99 ± 1.18 | 5.86 ± 1.25 |
IC measurement before and after metronome paced hyperventilation-induced dynamic hyperinflation at baseline and in tiotropium and placebo groups. Measure ratio of functional residual capacity divided by total lung capacity at baseline and after 30 days of tiotropium versus placebo
| liters | Before DH (Dynamic Hyperinflation) | After DH (Dynamic Hyperinflation |
|---|---|---|
| Baseline IC (inspiratory capacity) | 2.09 ± 0.83 | 1.76 ± 0.70 |
| Placebo IC | 2.17 ± 0.82 | 1.80 ± 0.70 |
| Tiotropium IC | 2.24 ± 0.80 | 1.80 ± 0.74 |
Total lung capacity before and after metronome paced hyperventilation induced dynamic hyperinflation in tiotropium cohort versus placebo. Difference between TLC measured at one hour before intervention \& 2 hrs. after after 30 days of treatment with either placebo or tiotropium
| liters | 2h Post Placebo TLC(L) | TLC (L) 2h Post Tiotropium |
|---|---|---|
| Before DH (dynamic hyperinflation) | 5.96 ± 1.22 | 5.84 ± 1.35 |
| After DH | 5.84 ± 1.13 | 5.78 ± 1.14 |
Correlation between improved lung function after tiotropium and extent of lung CT scored emphysema with respect to ratio functional residual capacity divided by total lung capacity. Specifically, correlation of tiotropium induced bronchodilation and extent of lung ct scored emphysema
| percentage of lung tissue | Lung CT Scored Emphysema and FRC/TLC |
|---|---|
| Extent of Lung CT Scored Emphysema and and Lung Function of FRC/TLC (Functional Residual Capacity(L)/Total Lung Capacity (L) After Tiotropium | 13.68 ± 18.84 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tiotropium Bromide 18 µg, Capsule, | — | 0/30 (0%) | 0/30 (0%) |
| Placebo | — | 0/30 (0%) | 0/30 (0%) |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 17 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 11 |
| Male | 18 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| United States | 23 |
| Canada | 6 |
| Average participant age +/- SD(years) | Entire Study Population |
|---|---|
| Mean | 70 ± 9 |
| FVC (forced vital capacity)(liters) | Entire Study Population |
|---|---|
| FVC (L) | 2.9 ± 1.2 |
| FVC (L) post 180 µg albuterol sulfate MDI | 3.3 ± 1.2 |
| FVC(percentage of liters expected) | Entire Study Population |
|---|---|
| FVC percent of liters predicted | 86 ± 17 |
| FVC post 180 µg albuterol percent of ltrs predict | 95 ± 16 |
| FEV1(L) (forces expiratory volume) observed(liters) | Entire Study Population |
|---|---|
| FEV1(L) | 1.6 ± 0.6 |
| FEV1(L) post 180 ug albuterol sulfate MDI | 1.8 ± 0.6 |
| FEV1 (L) percent predicted(percentage of liters expected) | Entire Study Population |
|---|---|
| FEV1 percent liters predicted | 61 ± 69 |
| FEV1 percent liters predicted post albuterol | 8 ± 6 |
10 further baseline measures are reported on the registry.
Plan to share: No — Please see published data
The record gives a start of Oct 2006, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Gelb, Arthur F., M.D.